Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of Illinois on behalf of investors who purchased BioSante Pharmaceuticals, Inc. (“BioSante” or the “Company”) (Nasdaq: BPAX) stock between February 8, 2010 and December 15, 2011.
For more information, click here:
. There is no cost or obligation to you.
The lawsuit alleges that during the Class Period BioSante overstated the viability, effectiveness and market potential of its experimental drug LibiGel. On December 14, 2011, the Company disclosed that LibiGel failed to yield positive results in efficacy tests. Upon this news, shares of BioSante stock plummeted from a trading high of $2.65 on December 14, 2011 to a close of $0.48 on December 15, 2011.
If you suffered a loss in BioSante you have until April 6, 2012
to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at
or by telephone at (877) 363-5972, or visit
Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:Levi & Korsinsky, LLPJoseph Levi, Esq.Eduard Korsinsky, Esq.30 Broad Street - 24th FloorNew York, NY 10004Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171